Continuation of long-term care for cervical dystonia at an academic movement disorders clinic.

Author: CharlesDavid, CookJason A, GillChandler E, ManusNeil D, MolinariAnna L, PelsterMichael W, TitleWallace

Paper Details 
Original Abstract of the Article :
Patients with cervical dystonia (CD) receive much of their care at university based hospital outpatient clinics. This study aimed to describe the clinical characteristics and treatment experiences of patients who continued care at our university based movement disorders clinic, and to document the r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705291/

データ提供:米国国立医学図書館(NLM)

Continuing Long-Term Care for Cervical Dystonia: A Look into Patient Experiences

In the field of movement disorders, providing long-term care for cervical dystonia (CD) patients is a crucial endeavor. This study, conducted at an academic movement disorders clinic, delves into the clinical characteristics and treatment experiences of patients who continued their care at the clinic. The researchers aimed to understand why a subset of patients chose to discontinue their care. They found that botulinum neurotoxin (BoNT) injection was the primary treatment modality, with onabotulinumtoxinA being the initial choice for most patients. However, a significant number of patients (30%) ultimately discontinued their care. The most common reasons cited were suboptimal response to BoNT therapy, excessive cost, travel burden, and side effects of BoNT therapy.

Addressing Barriers to Access for Effective Treatment

This research highlights the challenges faced by CD patients, particularly regarding access to care. The study emphasizes the need for initiatives that address these barriers, such as reducing out-of-pocket costs and training community physicians on neurotoxin injection techniques. These measures would not only improve patient access to care but also potentially reduce the travel burden experienced by patients seeking specialized treatment.

The Importance of Accessible and Affordable Treatment

From a health perspective, it is crucial to ensure that patients with CD have equitable access to effective treatment. The high discontinuation rate due to cost and travel highlights the need for a more accessible and affordable healthcare system.

Dr.Camel's Conclusion

This study sheds light on the challenges faced by patients with CD in accessing long-term care. As a researcher who has spent many years studying the nuances of movement disorders, I can say that this research is a valuable contribution to the field. It serves as a reminder that accessible and affordable healthcare is essential for patients with chronic conditions. It's like traversing a vast desert – a patient needs reliable access to an oasis, or in this case, a clinic, to sustain their health and well-being.

Date :
  1. Date Completed 2013-10-21
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23612751

DOI: Digital Object Identifier

PMC3705291

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.